- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01776723
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML) and Cataloging the Molecular Consequences of JAK2 Inhibition in Chronic Myelomonocytic Leukemia: A Correlative Study Identifying Targetable CMML Sub-Clones by Leveraging GM-CSF Dependent pSTAT Hypersensitivity
Study Overview
Detailed Description
This is a phase 1/2, two-stage, sequential cohort dose escalation study. If dose escalation is completed as planned, no more than 53 subjects are expected to enroll onto this study at a rate of approximately 3 subjects every month. For the Phase 2 study the Simon's optimal two-stage design will be employed to test the null hypothesis that response rate (RR) equals to 10% versus the alternative that RR equals to 30%.
Demographic and clinical variables for the study patients will be summarized using descriptive statistics (mean, standard deviation, median, inter-quartile range, range, and frequency counts and percentages). Safety and efficacy data will be analyzed overall as well as separately for each dose cohort when appropriate.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
New York
-
New York, New York, United States, 10021
- Weill Medical College of Cornell
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Cleveland Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmed diagnosis of CMML using the World Health Organization (WHO) classification
- Age >18 years at the time of obtaining informed consent
- Must be able to adhere to the study visit schedule and other protocol requirements
- Must be able to provide adequate bone marrow (BM) aspirate and biopsy specimens for histopathological analysis and standard cytogenetic analysis during the screening procedure
- An Eastern Cooperative Oncology Group (ECOG) performance status score of 0,1, or 2
- Women of childbearing potential must have a negative pregnancy test at time of screening and baseline visits and agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study.
- Must understand and voluntarily sign an informed consent form
- Must have a life expectancy of greater than 3 months at time of screening
Exclusion Criteria:
- Platelet count of less than 35,000/uL
- Absolute Neutrophil Count (ANC) of less than 250/uL
- Serum Creatinine >2.0
- Serum total bilirubin >1.5 x upper limit of normal (ULN)
- Use of cytotoxic chemotherapeutic agents, or experimental agents (agents that are not commercially available) for the treatment of CMML within 28 days of the first day of study drug treatment
- Any serious medical condition or psychiatric illness that will prevent the subject from signing the informed consent form or will place the subject at unacceptable risk if he/she participates in the study
- Concurrent use of Granulocyte/macrophage colony stimulating factor (GM-CSF). Granulocyte colony-stimulating factor (G-CSF) could be used for the short-term management of neutropenic infection. Stable doses of erythropoietin stimulating agents that were started >8 weeks from first ruxolitinib dose or corticosteroids that were being administered prior to screening are allowed.
- Uncontrolled current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study because ruxolitinib has not been studied in pregnant subjects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ruxolitinib, breastfeeding should be discontinued if the mother is treated with ruxolitinib.
- Patients who have participated in other interventional (treatment-related) clinical trials within 30 days of enrollment are excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: I: Dose Escalation - Ruxolitinib
Phase I: Dose Escalation.
In Phase I, participants will be allocated to dose levels starting at 10 mg/d (twice a day [BID] dosing) according to the "rolling six" Phase I design.
|
In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to 40mg/d.
The starting dose will be 10 mg/d (5mg BID).
Each cohort will include up to 6 subjects.
Once MTD is reached, 10 additional participants will be treated during the first stage of Phase II (stage 1) at the MTD.
Other Names:
|
EXPERIMENTAL: II: Maximum Tolerated Dose - Ruxolitinib
Phase II: Treatment at Maximum Tolerated Dose (MTD).
|
In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to 40mg/d.
The starting dose will be 10 mg/d (5mg BID).
Each cohort will include up to 6 subjects.
Once MTD is reached, 10 additional participants will be treated during the first stage of Phase II (stage 1) at the MTD.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Maximum Tolerated Dose (MTD) of Ruxolitinib for the Treatment of Myelomonocytic Leukemia (CMML)
Time Frame: 17 weeks
|
Phase I - The MTD is defined as the highest dose where less than 33% of participants experience a drug related predefined dose limited toxicity (DLT).
Dose-limiting toxicity (DLT) is defined as any grade 4 hematologic toxicity and any grade 3 or greater non-hematologic toxicity except nausea that is controlled by antiemetic therapy based on the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Grade 3 metabolic/electrolyte abnormalities that are not clinically significant, and are adequately controlled within 72 hours are not to be considered a DLT.
|
17 weeks
|
Occurrence of Clinical Response
Time Frame: Up to 2 years
|
Phase II - Proportion of participants achieving clinical benefit defined as hematologic improvement, complete remission (CR), partial remission (PR), marrow complete remission (Marrow CR) or stable disease (SD) by the International Working Group (IWG) 2006 criteria.
Erythroid Response for pretreatment hemoglobin < 11 g/dl; Platelet response for subjects with a pre-treatment platelet count < 50 x 10^9/L; Neutrophil response with pretreatment absolute neutrophil count (ANC) < 1 x 10^9/L.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Acute Myeloid Leukemia (AML) Transformation
Time Frame: Up to 2 years
|
Phase II - To determine the time to AML transformation of participants on Ruxolitinib.
Acute myeloid leukemia (AML) transformation according to World Health Organization (WHO) criteria.
CMML-1: peripheral blood <5% blasts, bone marrow <10% myeloblast.
CMML-2: peripheral blood <19 percent blasts persistent monocytosis >1000/ul +/- cytopenias Leukocytosis frequent, bone marrow <19 percent blasts >10% dysplasia in affected lineage, Auer Rods.
|
Up to 2 years
|
Median Overall Survival (OS)
Time Frame: Up to 2 years
|
Phase II - To determine the median overall survival.
|
Up to 2 years
|
Duration of Response in Days
Time Frame: 3.5 years
|
Phase II - To determine the duration of response achieved as in secondary endpoint one.
The duration of response is measured from the time measurement criteria are met for major or complete platelet response (which ever is first recorded) until the first date that disease progression defined by the bone marrow response outlined above, progression/relapse following a CR, marrow CR or PR, or progressions/relapse following hematological improvement (HI) as outlined above.
|
3.5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Eric Padron, M.D., H. Lee Moffitt Cancer Center and Research Institute
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MCC-17259
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelomonocytic Leukemia
-
Humanigen, Inc.CompletedChronic Myelomonocytic Leukemia (CMML)United States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedJuvenile Myelomonocytic LeukemiaUnited States, Canada, Australia, New Zealand
-
University of UtahCelgeneCompletedChronic Myelomonocytic LeukemiaUnited States
-
Arbeitsgemeinschaft medikamentoese TumortherapieCelgene CorporationUnknownChronic Myelomonocytic LeukemiaAustria
-
Groupe Francophone des MyelodysplasiesJanssen-Cilag Ltd.CompletedChronic Myelomonocytic LeukemiaFrance
-
University of ArkansasTerminatedChronic Myelomonocytic LeukemiaUnited States
-
Centre Hospitalier Universitaire de NiceUnknownChronic Myelomonocytic LeukemiaFrance
-
National Cancer Institute (NCI)CompletedJuvenile Myelomonocytic LeukemiaUnited States
-
M.D. Anderson Cancer CenterRecruitingMyelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia-1 | Chronic Myelomonocytic Leukemia-2 | Chronic Myelomonocytic Leukemia-0United States
-
Mayo ClinicRecruitingRecurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic LeukemiaUnited States
Clinical Trials on Ruxolitinib
-
First Affiliated Hospital of Zhejiang UniversityXiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaboratorsRecruitingHematologic Malignancy | Bronchiolitis Obliterans SyndromeChina
-
Novartis PharmaceuticalsTerminatedMyelofibrosis With High Molecular Risk MutationsBelgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
-
Incyte CorporationCompleted
-
University of ZurichIncyte CorporationNot yet recruitingExanthema | Lichenoid Skin Rashes Under Anti-PD1 Tumor Therapy
-
Beijing Friendship HospitalUnknownHemophagocytic LymphohistiocytosisChina
-
Julie NangiaIncyte Corporation; Translational Breast Cancer Research ConsortiumRecruitingDuctal Carcinoma In Situ | Atypical Ductal Hyperplasia | Atypical Lobular Hyperplasia | Lobular Carcinoma In SituUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingSevere Aplastic Anemia | Single Lineage Cytopenias, T-LGL | Hypoplastic MDSUnited States
-
Qilu Hospital of Shandong UniversityRecruiting
-
Memorial Sloan Kettering Cancer CenterDana-Farber Cancer Institute; Thomas Jefferson University; Cornell UniversityRecruiting
-
Children's Hospital Medical Center, CincinnatiCompletedSolid Organ Transplant | Acute-graft-versus-host Disease | Chronic Graft-versus-host-diseaseUnited States